# Cell-mediated Immunity for Prevention of CMV Disease

> **NCT02538172** · NA · COMPLETED · sponsor: **University of Lausanne Hospitals** · enrollment: 195 (actual)

## Conditions studied

- Cytomegalovirus Infections

## Interventions

- **OTHER:** T-Track® CMV assay

## Key facts

- **NCT ID:** NCT02538172
- **Lead sponsor:** University of Lausanne Hospitals
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2019-12
- **Final completion:** 2021-01
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2021-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02538172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02538172, "Cell-mediated Immunity for Prevention of CMV Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02538172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*